FDA Approved: JYNARQUE — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for JYNARQUE (tolvaptan) from Otsuka America Pharmaceutical, Inc. The action concerns autosomal dominant polycystic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JYNARQUE (tolvaptan)

Snippet

SUPPL AP for JYNARQUE (TOLVAPTAN)